Pharmaceutical Stocks

Pharmaceutical stocks have grown tremendously as medicine advances. With diseases like Covid-19, diabetes, liver disease and other illnesses affecting more and more of the population, pharmaceutical companies are racing to find cures – further advancing medicine and driving pharma stock prices higher.

Big Pharma corporations like AstraZeneca, Merck & Co., Pfizer, and Johnson & Johnson are leading the charge against the novel coronavirus, competing with smaller biotech names — such as Moderna and Novavax. The race to find a Covid-19 vaccine has sent both pharma and biotech stocks to the moon.

Sanofi Relies on Shopping to Offset Patent Losses on Key Drugs

By Barry Cohen, Health Care Writer
French drug giant Sanofi (SNY) is counting on mergers and acquisitions to restore profit growth amid a slew of patent expirations.

Pfizer Pushes to Keep Lipitor Profits Flowing

By Barry Cohen, Health Care Writer
Efforts to preserve the lucrative cholesterol-drug's franchise have sparked an antitrust suit. But competition is inevitable.

10 Companies Increasing Dividends

By Jim Woods, Editor-in-Chief, Successful Investing, Intelligence Report, Bullseye Stock Trader
Merck and ADP top the list of stocks increasing dividends this week. See eight other companies making shareholders smile.

Amylin Stumbles After Lilly Pulls Partnership Plug

By Barry Cohen, Health Care Writer
As Eli Lilly looks elsewhere for a diabetes drug partner, Amylin Pharmaceuticals stumbles. But Lilly is happy as can be. Here's why.

Hepatitis C Drug Progress Puts Several Companies on Acquisition Watch

By Barry Cohen, Health Care Writer
With their hepatitis C drugs showing promise in trials, these drug makers have become attractive targets for bigger pharma players.

Pharma Firms Duke It Out — Monday’s IP Market Recap

By Kyle Woodley, Senior Investing Editor, Kiplinger
Pharmasset (VRUS) and Inhibitex (INHX) jump on positive hepatitis C drug news, and Vertex (VRTX) stock gets knocked back.

3 Reasons Why Alexion Is the Real Deal

By Susan J. Aluise, Aviation, Auto & Transportation Writer
Alexion's fundamentals and strength in a narrow category of drugs called biopharmaceuticals make ALXN a promising stock.

Medivation Shares Shoot Up on Prostate Cancer Treatment News

By Barry Cohen, Health Care Writer
Medivation (MDVN) gains almost 140% Thursday on encouraging results for its prostate cancer treatment, and Dendreon (DNDN) is further battered.

Why Dendreon Is Aiming Prostate Drug Pitches to Consumers

By Barry Cohen, Health Care Writer
Dendreon (DNDN) appears to be pulling out all the stops in an effort to restore at least some of the luster to its prostate cancer treatment Provenge.

Jump Into Walgreen on the Cheap; Ditch CVS

By Will Ashworth, InvestorPlace Contributor
Walgreens (WAG) might actually benefit from a breakup with Express Scripts, and its standing as a Dividend Aristocrat doesn't hurt its case, either.

Top 5 Blue-Chip Stocks to Buy

By Louis Navellier, Editor, Growth Investor
There are two great sectors to play now -- and these are their finest blue-chip offerings. Pick up these shares before it's too late.

Amgen Bids for a Return to Favor

By Barry Cohen, Health Care Writer
Amgen's (AMGN) third-quarter earnings, budget management and full-year outlook turn positive, boosting the company's market prospects.

Take the Cure — Sell J&J, Buy GSK

By Will Ashworth, InvestorPlace Contributor
Johnson & Johnson and GlaxoSmithKline both have solid balance sheets, but GSK is poised to outperform its competitor.

9 Recession-Proof Biotech Stocks To Cure What Ails You

By Louis Navellier, Editor, Growth Investor
Health care stocks stay firm during a down economy and investors should consider up-and-coming biotech stocks like Alexion, Alkermes, Biogen and Cepheid.

Alexion Pharma Offers a Prescription for Profits

By John Kmiecik, InvestorPlace Contributor
ALXN has been on a slow and steady climb, and is an excellent candidate for options income with covered calls.

Should You Buy the Dow — Pfizer

By Lawrence Meyers, InvestorPlace Contributor
Pfizer's financials are decent, as is its lineup of drugs and personal care products, but the stock is fully valued.

Big Pharma Might Already Have Sights on Abbott Spinoff

By Barry Cohen, Health Care Writer
Abbott's Humira is a dollar-printing temptation for several companies, but Pfizer's tofacitinib could change the rheumatoid arthritis drug landscape.

Should You Buy the Dow — Merck

By Lawrence Meyers, InvestorPlace Contributor
Merck is a strong, old company with a good dividend -- it suits retirement accounts fine, but regular traders might want to keep their distance.

Is Abbott’s Spinoff the Beginning of a Trend?

By Barry Cohen, Health Care Writer
A look at Abbott Labs' (ABT) breakup indicates splitting up may be good medicine for other diversified health care companies.
Load More